Joshua M Bauml
13PUBLICATIONS
112CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Mar 03, 2026
JNJ-79032421, a Novel Membrane-restricted Mesothelin-targeting T-cell-engaging Bispecific Antibody for the Treatment of Mesothelin-positive Cancers.Karine Smans, Thomas Nesspor, Sabine De Breucker
|Dec 01, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.Pascale Tomasini, Yongsheng Wang, Yongsheng Li
|Jan 17, 2025
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.David E Gerber, Claire R Wynters, Tanushree Prasad
|Jun 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim
|May 15, 2023
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Charu Aggarwal, Alisha P Maity, Joshua M Bauml
|Dec 08, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancer.David G Pfister, Robert I Haddad, Francis P Worden
Pageof 3
Frequent Collaborators
4 joint publications
Melina E Marmarelis
3 joint publications
James Chih-Hsin Yang
3 joint publications
Alexander I Spira
2 joint publications
Stephanie S Yee
2 joint publications
Rachel E Sanborn
2 joint publications
Joshua K Sabari
2 joint publications
Ji-Youn Han
2 joint publications
Koichi Goto
2 joint publications
Natasha B Leighl
2 joint publications
Corey J Langer
